ADC Therapeutics(NYSE:ADCT) 
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical tria...
Website: http://www.adctherapeutics.com
Founded: 2011
CEO: Christopher John Martin
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.19
H 1.23
L 1.14
C 1.19
V 691,547
10EMA 1.19
20EMA 1.19
60EMA 1.19
120EMA 1.19
250EMA 1.19